AbbVie is talkin’ bout a resolution. The Big Pharma has bet $48 million on OSE Immunotherapeutics’ antibody platform, handing the biotech the upfront fee and dangling another $665 million in ...
OSAKA, Japan and NEW YORK, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Osaka Securities Exchange Co., Ltd. (OSE) has successfully launched its new derivatives trading system, "J-GATE", compliant with ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key ...
OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody ...
NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced that the Hart-Scott-Rodino waiting period has ...
OSE-CYTOMASK is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics that deliver highly active medicines with improved ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has received €200,000 grant innovation funding from the ...
Osé, the sex toy that received a CES Innovation Award, lost it, and then won it back again, is finally ready to pre-order. The device sparked a debate about gender bias in the tech industry and what ...
NANTES, France - March 26, 2025, 6:15 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback